Sana M. Al-Khatib

Sana M. Al-Khatib

Auto-generated profile, based on publicly available information

Sana M. Al-Khatib

Division of Cardiology, Duke University Medical Center, Durham, NC (S.M.A.-K.).

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 April 2003 in JAMA
Verified
Journal Article
Closed access
PDF file
SASana M. Al-Khatib
Sana M. Al-Khatib
NLNancy M. Allen LaPointe
Nancy M. Allen LaPointe
JKJudith M. Kramer
Judith M. Kramer
RCRobert M. Califf
Robert M. Califf
Research from JAMA — What Clinicians Should Know About the QT Interval — ContextOf the several factors implicated in causing QT interval prolongation and torsades de pointes, errors in the use of medications that may prolong this interval deserve special attention.ObjectiveTo systematically summarize the available clinical data on the QT interval and to offer improved recommendations for the use of QT-prolonging medications.Data SourcesWe searched MEDLINE from 1966 through 2002 for all English-language articles related to the QT interval. Additional data sources included bibliographies of articles identified on MEDLINE, a survey of experts, and data presented at a meeting of experts on long QT syndrome.Study SelectionWe selected for review registries and case series examining clinical outcomes of patients with prolonged QT interval and the effect of different methods of measurement of the QT interval on patient outcomes. Ten studies were identified, of which 6 were included in the analysis.Data ExtractionData quality was determined by publication in the peer-reviewed literature.Data SynthesisOptimal measurement of the QT interval is problematic because of lack of standardization and lack of data regarding the best way to adjust for heart rate. Reliable information on the proper use of QT-prolonging medications is scarce. Although a QT interval of at least 500 milliseconds generally has been shown to correlate with a higher risk of torsades de pointes, there is no established threshold below which prolongation of the QT interval is considered free of proarrhythmic risk. The risk of torsades de pointes should be assessed in patients who are about to begin taking a QT-prolonging medication. Although inadequate clinical studies preclude prediction of absolute risk for individual patients, particularly high-risk situations can be defined based on clinical variables. We propose recommendations on proper monitoring of the QT interval in patients receiving QT-prolonging medications.ConclusionAlthough the use of QT-prolonging medications can predispose to torsades de pointes, there is a relative paucity of information that can help clinicians and patients make optimal informed decisions about how best to minimize the risk of this serious complication.

5 January 2011 in JAMA
Verified
Journal Article
Open access
PDF file
SASana M. Al-Khatib
Sana M. Al-Khatib
AHAnne Hellkamp
Anne Hellkamp
JCJeptha Curtis
Jeptha Curtis
DMDaniel Mark
Daniel Mark
EPEric Peterson
Eric Peterson
SHStephen Hammill
Stephen Hammill
Several randomized controlled trials have proven the efficacy of the implantable cardioverter-defibrillator (ICD) at preventing sudden cardiac death in patients with advanced systolic heart failure.1-3 These trials excluded patients who were in the acute phase of a myocardial infarction (MI), had recent coronary revascularization, had New York Heart Association (NYHA) class IV symptoms, or had newly diagnosed heart failure. In other clinical trials, survival benefit from ICD therapy could not be demonstrated in patients recovering from an acute MI and patients who received an ICD at the time of coronary artery bypass graft (CABG) surgery.4-6

3 June 2014 in Annals of Internal Medicine
Verified
Journal Article
Closed access
PDF file
SASana M. Al-Khatib
Sana M. Al-Khatib
NLNancy M. Allen LaPointe
Nancy M. Allen LaPointe
RCRanee Chatterjee
Ranee Chatterjee
MCMatthew J. Crowley
Matthew J. Crowley
MDMatthew E. Dupre
Matthew E. Dupre
GSGillian D. Sanders
Gillian D. Sanders
The comparative effectiveness of treatments for atrial fibrillation (AF) is uncertain. To evaluate the comparative effectiveness of rate- and rhythm-control therapies. English-language studies in PubMed, EMBASE, and the Cochrane Database of Systematic Reviews between January 2000 and November 2013. Two reviewers independently screened citations to identify comparative studies that assessed rate- or rhythm-control therapies in patients with AF. Reviewers extracted data on study design, participant characteristics, interventions, outcomes, applicability, and quality. 200 articles (162 studies) involving 28 836 patients were included. When pharmacologic rate- and rhythm-control strategies were compared, strength of evidence (SOE) was moderate supporting comparable efficacy with regard to all-cause mortality (odds ratio [OR], 1.34 [95% CI, 0.89 to 2.02]), cardiac mortality (OR, 0.96 [CI, 0.77 to 1.20]), and stroke (OR, 0.99 [CI, 0.76 to 1.30]) in older patients with mild AF symptoms. Few studies compared rate-control therapies and included outcomes of interest, which limited conclusions. For the effect of rhythm-control therapies in reducing AF recurrence, SOE was high favoring pulmonary vein isolation versus antiarrhythmic medications (OR, 5.87 [CI, 3.18 to 10.85]) and the surgical maze procedure (including pulmonary vein isolation) done during other cardiac surgery versus other cardiac surgery alone (OR, 7.94 [CI, 3.63 to 17.36]). Studies were heterogeneous in interventions, populations, settings, and outcomes. Pharmacologic rate- and rhythm-control strategies have comparable efficacy across outcomes in primarily older patients with mild AF symptoms. Pulmonary vein isolation is better than antiarrhythmic medications at reducing recurrences of AF in younger patients with paroxysmal AF and mild structural heart disease. Future research should address uncertainties related to subgroups of interest and the effect of different therapies on long-term clinical outcomes. Agency for Healthcare Research and Quality.

17 April 2013 in European Heart Journal
Verified
Journal Article
Open access
PDF file
SASana M. Al-Khatib
Sana M. Al-Khatib
LTLaine Thomas
Laine Thomas
LWLars Wallentin
Lars Wallentin
RLRenato D. Lopes
Renato D. Lopes
BGBernard Gersh
Bernard Gersh
CGChristopher B. Granger
Christopher B. Granger
It is uncertain whether the benefit from apixaban varies by type and duration of atrial fibrillation (AF). A total of 18 201 patients with AF [2786 (15.3%) with paroxysmal and 15 412 (84.7%) with persistent or permanent] were randomized to apixaban or warfarin. In this pre-specified secondary analysis, we compared outcomes and treatment effect of apixaban vs. warfarin by AF type and duration. The primary efficacy endpoint was a composite of ischaemic or haemorrhagic stroke or systemic embolism. The secondary efficacy endpoint was all-cause mortality. There was a consistent reduction in stroke or systemic embolism (P for interaction = 0.71), all-cause mortality (P for interaction = 0.75), and major bleeding (P for interaction = 0.50) with apixaban compared with warfarin for both AF types. Apixaban was superior to warfarin in all studied endpoints, regardless of AF duration at study entry (P for all interactions >0.13). The rate of stroke or systemic embolism was significantly higher in patients with persistent or permanent AF than patients with paroxysmal AF (1.52 vs. 0.98%; P = 0.003, adjusted P = 0.015). There was also a trend towards higher mortality in patients with persistent or permanent AF (3.90 vs. 2.81%; P = 0.0002, adjusted P = 0.066). The risks of stroke, mortality, and major bleeding were lower with apixaban than warfarin regardless of AF type and duration. Although the risk of stroke or systemic embolism was lower in paroxysmal than persistent or permanent AF, apixaban is an attractive alternative to warfarin in patients with AF and at least one other risk factor for stroke, regardless of the type or duration of AF.

1 October 2005 in JACC
Verified
Journal Article
Closed access
SASana M. Al-Khatib
Sana M. Al-Khatib
FLF. Lee Lucas
F. Lee Lucas
JJJames G. Jollis
James G. Jollis
DMDavid J. Malenka
David J. Malenka
DWDavid E. Wennberg
David E. Wennberg

1 November 2016 in JAMA Cardiology
Verified
Journal Article
Closed access
PDF file
DFDaniel J. Friedman
Daniel J. Friedman
CPCraig S. Parzynski
Craig S. Parzynski
PVPaul D. Varosy
Paul D. Varosy
JPJordan M. Prutkin
Jordan M. Prutkin
KPKristen K. Patton
Kristen K. Patton
SASana M. Al-Khatib
Sana M. Al-Khatib
Multiple randomized clinical trials have identified the implantable cardioverter defibrillator (ICD) as the treatment of choice for reducing the risk of death due to sustained ventricular arrhythmias among patients with a history of1-4 or at high risk for5-9 ventricular arrhythmias. The mortality benefit conferred by the ICD in these populations has led to its widespread use; approximately 150 000 ICDs (73.8% primary prevention) are implanted in the United States annually.10